An observational study in Pancreatic Cancer, sponsored by Medizinische Hochschule Brandenburg Theodor Fontane. Completed at 1 site in Germany. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-04-21.
Sponsored by Medizinische Hochschule Brandenburg Theodor Fontane · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies in Pancreatic Neoplasms with a site in Germany — 24 open to participants now, 35 under way, 10 of them phase 3. Pancreatic Neoplasms · Germany.
Among the 175 studies in Pancreatic Neoplasms with a site in Germany, this one is the 7th largest by enrollment of the 29 observational ones that give a count, is one of 12 that started in 2017, is one of 29 observational ones, and was the 173rd registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →24 of the 175 studies in Pancreatic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany, United States, Belgium and 10 more countries
Ages 18+
Immuneering Corporation · Sites in Germany, United States, Australia and 6 more countries
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 18+
Incyte Corporation · Sites in Germany, United States, Australia and 19 more countries
Ages 18+
Revolution Medicines, Inc. · Sites in Germany, United States, Australia and 18 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 89 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 40 · Phase 2 69 · Phase 3 44
First in 1997; this study’s year is marked. 12 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,048 is above the median of 200 across 743 observational studies indexed under Pancreatic Neoplasms.
Median enrollment 122 across the 143 interventional studies, 338 across the 29 observational. Of the 118 that completed or were terminated, 38 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 175 have an industry lead sponsor. The 10 most frequent:
Medizinische Hochschule Brandenburg Theodor Fontane is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Medizinische Hochschule Brandenburg Theodor Fontane has 2 studies filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Pancreatic Neoplasms with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT04421820Bold Therapeutics, Inc.BOLD-100 in Combination With FOLFOX With or Without Bevacizumab for the Treatment of Advanced, Solid Tumours | 2027-07-01 |
| NCT07280377Oncolytics BiotechA Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 175 studies in Pancreatic Neoplasms with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looks at how different treatment approaches affect survival in older people with pancreatic cancer that has not spread to other parts of the body. In particular, it focuses on patients aged 80 years and older who are still in relatively good general health and able to carry out normal daily activities.
Pancreatic cancer is a serious disease, and surgery to remove the tumor is often the only treatment that offers a chance of longer survival. However, older patients are less likely to receive surgery, even if they are otherwise fit. Doctors may hesitate to recommend surgery mainly because of the patient's age, rather than their overall health condition. This study aims to better understand whether surgery can still be beneficial for these older patients.
The study also examines the role of additional treatment after surgery, such as chemotherapy. In real-world medical practice, not all patients receive this follow-up treatment, especially older individuals who may have a slower recovery after surgery. This can make it difficult to understand whether such treatments truly improve survival.
To answer these questions, the study uses data from a large cancer registry in Germany. It compares patients who had surgery with those who did not, and it also looks at patients who received additional treatment after surgery versus those who did not. Special methods are used to take into account that some patients may not have been able to receive further treatment because they did not recover well enough after surgery.
The results of this study are intended to help doctors make better treatment decisions for older patients with pancreatic cancer, focusing more on their overall health and less on age alone.
This study is a retrospective, population-based cohort analysis designed to evaluate treatment outcomes in patients with non-metastatic pancreatic cancer, with a particular focus on older individuals aged 80 years and above who have a good functional status.
Pancreatic cancer is one of the most serious forms of cancer, with generally poor survival outcomes. Surgical removal of the tumor represents the only potentially curative treatment option. However, the use of surgery in elderly patients remains controversial. In routine clinical practice, treatment decisions are often influenced by chronological age rather than a patient's actual physical condition. As a result, older patients are less likely to undergo surgical treatment, even when they may be fit enough to tolerate it.
In addition to surgery, chemotherapy administered after tumor removal is commonly recommended to improve long-term outcomes. Evidence from clinical trials suggests that this additional treatment can prolong survival. However, these trials typically include highly selected patients who have recovered well from surgery and meet strict eligibility criteria. In contrast, in everyday clinical practice, many patients-especially older ones-may not receive such treatment due to complications, slower recovery, or reduced tolerance.
This study aims to address these gaps by analyzing real-world data from the Clinical-Epidemiological Cancer Registry of Berlin and Brandenburg, Germany. The registry collects standardized information on cancer diagnosis, treatments, and outcomes across both hospital and outpatient settings. Data completeness is ensured through mandatory reporting requirements and validation processes.
The study includes patients diagnosed with pancreatic cancer between January 1, 2017, and December 31, 2023. Only patients with disease that has not spread to distant organs (stages I to III) are included. To ensure comparability and reduce the influence of frailty, the analysis is limited to patients with good general condition, defined as being fully active or only slightly restricted in physical activity. Patients aged 90 years and older are excluded due to small numbers and expected heterogeneity.
Two main research questions are addressed:
First, the study evaluates whether surgical removal of the tumor is associated with improved overall survival, particularly in patients aged 80 years and older. Patients are grouped according to whether they underwent surgery or not, and survival outcomes are compared between these groups. Analyses are adjusted for relevant patient and disease characteristics to reduce potential confounding.
Second, the study examines the association between postoperative chemotherapy and survival in patients who underwent complete tumor removal without prior treatment. This part of the analysis focuses on patients who had no remaining visible tumor after surgery and did not receive treatment before surgery.
A key methodological challenge in evaluating postoperative treatments is that only patients who recover sufficiently after surgery can receive additional therapy. This introduces a potential bias, as these patients may already have a better prognosis. To address this issue, the study applies two complementary analytical strategies.
In the first approach, survival is measured starting from the time of surgery, and patients are grouped based on whether they received postoperative treatment. In the second approach, a so-called landmark analysis is performed. In this analysis, patients who die within the first 90 days after surgery are excluded, and survival is measured starting from this fixed time point. This method helps to reduce bias related to early postoperative mortality and differences in recovery.
Statistical analyses include survival estimation using time-to-event methods and multivariable regression models to adjust for differences between patient groups. Key variables considered in the analysis include age, sex, tumor stage, and general health status.
The findings of this study are intended to provide clinically relevant evidence for treatment decision-making in older patients with pancreatic cancer. By focusing on real-world data and applying methods to address potential biases, the study aims to improve understanding of how surgery and postoperative treatment affect survival in this growing patient population.
All residents of the Federal States Brandenburg and Berlin
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: All types of surgical tumor resection procedures with curative intent · Procedure: No surgical resection
Procedure: All types of surgical tumor resection procedures with curative intent · Procedure: No surgical resection
Overall Survival
Time frame: 1 year overall survival after index surgery
Plan to share: No — Individual participant data (IPD) cannot be shared. The data used in this study were obtained from a regional clinical cancer registry and are subject to strict data protection regulations. The dataset contains sensitive, potentially identifiable health information and is governed by legal restrictions that prohibit public data sharing.
No publications or documents are linked to this record.
Ran from Jan 2017 to primary completion in Dec 2023, 83 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medizinische Hochschule Brandenburg Theodor Fontane